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Abstract
Drug-target interaction (DTI) is the basis of drug discovery and design. It is time consuming and costly to determine DTI
experimentally. Hence, it is necessary to develop computational methods for the prediction of potential DTI. Based on
complex network theory, three supervised inference methods were developed here to predict DTI and used for drug
repositioning, namely drug-based similarity inference (DBSI), target-based similarity inference (TBSI) and network-based
inference (NBI). Among them, NBI performed best on four benchmark data sets. Then a drug-target network was created
with NBI based on 12,483 FDA-approved and experimental drug-target binary links, and some new DTIs were further
predicted. In vitro assays confirmed that five old drugs, namely montelukast, diclofenac, simvastatin, ketoconazole, and
itraconazole, showed polypharmacological features on estrogen receptors or dipeptidyl peptidase-IV with half maximal
inhibitory or effective concentration ranged from 0.2 to 10 mM. Moreover, simvastatin and ketoconazole showed potent
antiproliferative activities on human MDA-MB-231 breast cancer cell line in MTT assays. The results indicated that these
methods could be powerful tools in prediction of DTIs and drug repositioning.
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Introduction
Over the past decade, the rate of new chemical entities tran-
sferred to therapeutic agents has been significantly decreased [1].
Interestingly, this phenomenon is concurrent with the dominant
assumption that the goal of drug discovery is to design exquisitely
selective ligands against a single target. However, this ‘one gene,
one drug, one disease’ paradigm was challenged in many cases,
and the concept of polypharmacology was hence proposed for
those drugs acting on multiple targets rather than one target [1].
For example, serotonin and serotonergic drugs not only bind to G
protein-coupled receptors (GPCRs) such as 5-hydroxytryptamine
receptors 1, 2 and 4–7 (5-HT1,2,4–7), but also might bind to an ion
channel, i.e. 5-HT3 [2,3]. Such polypharmacological features of
drugs enable us to understand drug side effects or find their new
uses, namely drug repositioning [4]. Some good examples are
thalidomide, sildenafil, bupropion and fluoxetine [4,5].
To date, several in silico methods have been developed to
address the issues of drug-target interaction (DTI) prediction and
drug repositioning [6–11]. The conventional methods can be
either ligand-based or receptor-based. Ligand-based methods like
quantitative structure-activity relationships (QSAR) and similarity
search are very useful in this context. For example, Keiser et al.
predicted new molecular targets for known drugs using chemical
two-dimensional (2D) structural similarity, namely similarity
ensemble approach [6,7]. Twenty-three new DTIs were confirmed
and five of which were potent with Ki values,100 nM. Recently,
Humberto et al. developed a multi-target QSAR (mt-QSAR)
classifier and built a web server for DTI prediction [8]. Receptor-
based methods like reverse docking have also been applied in drug-
target (DT) binding affinity prediction, DTI prediction and drug
repositioning [9–11].However, those methods could not be used for
targets whose three-dimensional (3D) structures are unknown.
More recently, several network-based and phenotype-based
methods were developed for such purposes. Yildirim et al. constructed
a bipartite graph composed of US Food and Drug Administration
(FDA)-approved drugs and proteins linked by DT binary associations
[12]. This method quantitatively showed an overabundance of
‘follow-on’ drugs. Campillos et al. identified new DTIs using side-
effect similarity [13]. They tested 20 of unexpected DTIs and
validated 13 ones by in vitro binding assays. Iorio et al. predicted and
validated new drug modes of action and drug repositioning from
transcriptional responses [14]. Recently Butte group also reported
two successful examples of drug repositioning based on public gene
expression data [15,16]. Furthermore, Yamanishi et al. developed a
bipartite graph learning method to predict DTI by integrating
chemical and genomic spaces [17]. Though high overall predictive
accuracy was obtained in Yamanishi’s work, the sensitivity was
anomaly low and the method was not validated experimentally.
PLoS Computational Biology | www.ploscompbiol.org 1 May 2012 | Volume 8 | Issue 5 | e1002503In this study, three inference methods were developed to predict
new DTI: drug-based similarity inference (DBSI), target-based
similarity inference (TBSI) and network-based inference (NBI), all
derived from complex network theory [18–21]. Four benchmark
data sets with known drugs targeting enzymes, ion channels,
GPCRs, and nuclear receptors respectively, were used to assess the
performance of the methods in comparison with literature reports.
The best-performed method was then selected to create a drug-
target network of FDA-approved and experimental drugs and to
predict new DTIs subsequently. Some of the predictions were
further validated by in vitro assays. This work would provide new
powerful tools for DTI prediction and drug repositioning.
Results
The methods developed here were derived from the recom-
mendation algorithms of complex network theory, and proposed
for DTI prediction and hence drug repositioning. In principle, the
DBSI method (Figure 1A) is very similar to the item-based
collaborative filtering method in recommendation algorithms [20],
while TBSI (Figure 1B) is similar to the user-based collaborative
filtering method [21]. Different from DBSI and TBSI, the NBI
method (Figure 1C) only uses known DT bipartite network
topology similarity to predict unknown DTI, which employs a
process analogous to mass diffusion in physics across the DT
network [18,19]. In NBI method, predictive scores are calculated
for each given drug (pink circle) and each unlinked target, and a
recommendation list of drugs was created for a given target (pink
square) in a descending order after the diffusion process.
Performance of the methods on benchmark data sets
Four benchmark data sets were used to assess the performance
of the methods. The data sets were named after four major drug
targets, i.e. enzymes, ion channels, GPCRs, and nuclear receptors.
At first, all known DTIs (Table S1) involved in the data sets were
used to generate a DT bipartite network (Figure S1), in which a
drug (circle) and a target (square) were connected if the target was
known to the drug according to experimental evidence.
Figure 2 illustrated the receiver operating characteristic (ROC)
curves calculated by the methods on the benchmark data sets using
the 30 simulation times of 10-fold cross validation, from which it is
easy to see that all methods performed well with high true positive
rate (TPR) against low false positive rate (FPR) at any threshold.
As shown in Figure 2, NBI always gave the best TPR values at any
FPR value, suggesting that the NBI method would have the
highest predictive ability among them. The average area under
ROC curve (AUC) values of NBI method by the 30 simulation
times of 10-fold cross validation were 0.97560.006, 0.97660.007,
0.94660.019 and 0.83860.087 for enzymes, ion channels,
GPCRs and nuclear receptors, respectively (Table S2).
Figure S2 illustrated precision (P) as a function of predicted
length (L) with different methods. For enzymes, ion channels and
GPCRs, the curves from up to down were yielded for NBI (dash
curve in the figure), TBSI (solid curve) and DBSI (dot dash curve)
subsequently, which coincided with the performance of AUC. For
nuclear receptors, the relation of the three curves was not so
regular as in the former three data sets, which suggested that data
completeness [22] should be important for DTI prediction because
there were only 90 DTI pairs in the nuclear receptor data set and
the average of known targets for a drug was less than 2 (Table S1).
Figure S3 illustrated recall (R) as a function of L with different
methods. The R value from NBI was much better than those from
TBSI and DBSI (Table S3). It should be highlighted that the R
value is the most important parameter in DTI modeling. A low R
value indicated the low ability of a model to recognize known
DTIs from complex DT networks.
Prediction of drug-target interactions
At first, a DT bipartite network was constructed with known
DTI data extracted from DrugBank [23]. As shown in Figure 3,
there were obviously polypharmacological features for many
approved drugs. For example, the promiscuous drug NADH was
connected with 95 proteins, while the promiscuous target a1A
adrenergic receptor was linked with 52 drugs. This comprehensive
mapping of pharmacological space enables us to predict new
indications for old drugs by our methods.
NBI method was then used to predict new DTI in the DT
bipartite network. To test the feasibility of NBI on DrugBank, the
performance was assessed by the 30 simulation times of 10-fold
cross validation. As shown in Figure S4, high AUC values of
0.86560.009 and 0.84960.012 were yielded with NBI for the
approved drugs and the global data set containing approved and
experimental drugs, respectively, which indicated that NBI
method is valid for DrugBank.
In order to validate the predictions experimentally, one enzyme,
DPP-IV, and two receptors, ERa and ERb, were selected as the
targets, just because the drug screening systems of these targets are
available in our laboratory. By applying NBI method on the global
DrugBank database, all new potential drugs targeted with DPP-
IV, ERa and ERb were predicted. Nine purchasable old drugs
were selected from top 50 recommended potential DPP-IV
inhibitors (Table S4), whereas 31 purchasable old drugs were
selected from top 80 recommended potential ER ligands (Tables
S5 and S6) for experimental assays.
Experimental validation of drug repositioning
All the 40 old drugs were purchased and tested by in vitro assays
accordingly. As shown in Figures 4 and 5, one approved drug, i.e.
montelukast, was identified from the 9 purchased compounds as
an unreported DPP-IV inhibitor with half maximal inhibitory
concentration (IC50)=9.79 mM. For ERa and ERb, four ap-
proved drugs, namely diclofenac, simvastatin, ketoconazole, and
Author Summary
Study of drug-target interaction is an important topic
toward elucidation of protein functions and understanding
of molecular mechanisms inside cells. Traditional methods
to predict new targets for known drugs were based on
small molecules, protein targets or phenotype features.
Here, we proposed a network-based inference (NBI)
method which only used drug-target bipartite network
topology similarity to infer new targets for known drugs.
The performance of NBI outperformed the drug-based
similarity inference and target-based similarity inference
methods as well as other published methods. Via the NBI
method five old drugs, namely montelukast, diclofenac,
simvastatin, ketoconazole, and itraconazole, were identi-
fied to have polypharmacological effects on human
estrogen receptors or dipeptidyl peptidase-IV with half
maximal inhibitory or effective concentration from sub-
micromolar to micromolar by in vitro assays. Moreover,
simvastatin and ketoconazole showed potent antiprolifer-
ative activities on human MDA-MB-231 breast cancer cell
line in MTT assays. The results indicated that the drug-
target bipartite network-based inference method could be
a useful tool for fishing novel drug-target interactions in
molecular polypharmacological space.
Drug Repositioning via Network-Based Inference
PLoS Computational Biology | www.ploscompbiol.org 2 May 2012 | Volume 8 | Issue 5 | e1002503Figure 1. Schematic diagram of (A) drug-based similarity inference (DBSI), (B) target-based similarity inference (TBSI) and (C)
network-based inference (NBI) methods. The entire workflow includes five steps: (i) collection of known drug-target interaction data and
construction of bipartite drug-target graphs; (ii) calculation of drug-drug two dimensional structural similarity (SC), target-target genomic sequence
similarity (Sg) and drug-target topology network similarity; (iii) application of new methods in prediction of new drugs for a given target (pink square)
or new targets for a given drug (pink circle); (iv) validation of new drug-target interactions by experimental assays (D); (v) visualization of
experimental results using drug-target-disease associations network analysis (E). In A–C, given drug node (pink circle) denotes the drug which we
want to predict new target for, given target node (pink square) denotes the target which we want to predict new drug for, drug with resource (green
circle) denotes that this drug have resource, target with resource (green square) denotes that this target have resource, the more resource a node
possesses, the darker the color is, blue edges denote the drug-target interactions with known experimental evidence, black arrows denote the
resource diffusion direction. In E, green circle: drug node, red square: on-target node, blue square: off-target node, yellow square: new off-target
node, violet square: disease node.
doi:10.1371/journal.pcbi.1002503.g001
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ligands with IC50 or half maximal effective concentration (EC50)
values less than 10 mM. Itraconazole was a dual-profile com-
pound, which showed agonistic activity with EC50 of 200 nM on
ERa but a higher antagonistic activity with IC50 of 280 nM on
ERb than tamoxifen, a classical anti-breast cancer drug.
Moreover, the antiproliferative potencies of diclofenac, simvasta-
tin,ketoconazole,anditraconazolewere evaluated on humanMDA-
MB-231breastcancercelllinebyMTTassays.AsshowninFigure6,
simvastatin and ketoconazole showed potent antiproliferative ac-
tivities with IC50 values of 1.49 mMa n d8 . 9 5mM, respectively.
Network visualization of validated drug-target
interactions
Network visualization of drug-target, target-disease and disease-
gene associations could provide helpful information for discovery
of new therapeutic indications or adverse effects of old drugs. As
illustrated in Figure 7, where disease-related genes and disorder-
disease gene associations (given in Table S7) were extracted from
Online Mendelian Inheritance in Man (OMIM) Morbid Map
[24], it is easy to see polypharmacological effects of the five old
drugs (cyan). For example, simvastatin originally inhibits HMG-
CoA reductase (on-target labeled with red square box) [23,25], but
it has more than 20 off-targets (gray square box) in Figure 7 [24].
In this study, simvastatin was validated to have antagonistic effects
on ERb with IC50 value at 3.12 mM and showed good anti-
proliferative activity on human MDA-MB-231 breast cancer cell
line with IC50 value of 1.49 mM (Figures 5 and 6).
Although some drugs act by binding to specific proteins, most of
FDA-approved drugs were developed without knowledge of
molecular mechanisms responsible for their indicated diseases.
For example, ketoconazole inhibits the production of testosterone,
and has been used by urologists to treat refractory bone pain and
impending neurologic injury in patients with advanced metastatic
prostate cancer [26,27], but the molecular mechanism is
unknown. In this study, ketoconazole was found to selectively
inhibit ERb with IC50 value of 0.79 mM and showed good
antiproliferative activity on human MDA-MB-231 breast cancer
cell line with IC50 value of 8.95 mM, which indicated that
ketoconazole may have more broad-spectrum anti-cancer indica-
tions with therapeutic effects of breast cancer in clinic.
Discussion
Comparison of the methods
In this study, three supervised inference methods, i.e. DBSI,
TBSI and NBI, were developed to predict new DTI. Excellent
performance was obtained for these methods on four benchmark
data sets, which outperformed some methods reported elsewhere
[17,28,29]. The essential difference of the three methods is the
definition of similarity. DBSI is based on chemical 2D structural
similarity, and TBSI is based on genomic sequence similarity,
whereas NBI is only based on DT bipartite network topology
similarity (Figure 1). The worse AUC values of DBSI on the
benchmark data sets indicated that the prediction based on
chemical structure similarity alone was poor (Figure 2). This may
be caused by the redundancy in the similarity. For example, in the
enzyme data set, though chemical structure similarity can present
drug similarity very accurately, similar structures without binding
to enzymes should be redundant to reduce the predictive accuracy.
There is a similar redundancy problem in TBSI. Although NBI is
the simplest one for ignoring structural information of drugs and
targets, the prediction is the most reliable (see box plot in Figure
Figure 2. The receiver operating characteristic (ROC) curves of the three different methods to predict new known drugs for a given
target on the four benchmark data sets by simulation 30 times of 10-fold cross validation test, (a) enzymes, (b) ion channels, (c)
GPCRs and (d) nuclear receptors, drug-based similarity inference (DBSI): dot dash curve, target-based similarity inference (TBSI):
solid curve, network-based inference (NBI): dash curve, FPR: false positive rate and TPR: true positive rate.
doi:10.1371/journal.pcbi.1002503.g002
Drug Repositioning via Network-Based Inference
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inferring new potential DTI, which did not need any 3D structural
information of targets and drugs. Therefore, NBI performed better
than DBSI, TBSI and other reverse docking methods [10,11].
Recently, Hansen et al. created four features from gene-drug
network and built a logistic classifier for drug-gene association
prediction [30]. Although high predictive performance were
obtained, an inherent problem in Hansen’s work is that the negative
drug-gene pairs were randomly constructed (selected on the basis of
unknown drug-gene associations), which easily brought noise in a
logisticclassifierbuildingbytheinaccuratenegativesampleselection.
Yamanishi et al. predicted new DTIs by integration of chemical and
genomic spaces. Reasonable AUC value was obtained, but the R
values were extremely poor, only 0.574, 0.271, 0.234 and 0.148 for
enzymes, ion channels, GPCRs, and nuclear receptors respectively
[17], and the predicted results were not validated experimentally.
Compared with those reported methods, NBI only used the simple
DTassociationinformationandyieldedhighpredictiveperformance
(R more than 0.9, Table S3). Chiang and Butte developed a guilt-by-
association method for disease-gene association prediction and drug
repositioning [31]. This method only used gene-disease linkage
information. In present study, NBI takes fully advantage of the
labeled and unlabeled information encoded in the full DT network
topology (Figure 1), thereby simultaneously exploiting both topolog-
ical and functional modularity.
Potential application of NBI in drug repositioning
Usually there are two major methods for DTI prediction and
drug repositioning: traditional drug discovery method, in which
new drugs or hits are predicted for a certain target; and chemical
biology method, where new potential targets are predicted for a
given drug or chemical [17]. In this study, NBI method inherited
the advantages of both methods. It can prioritize candidate drugs
for a given target or prioritize candidate targets for a given drug
simultaneously by personal recommendation [18,19]. With matrix
transposition, we could also prioritize new potential targets for a
given drug. As shown in Figure S6, the high performance was
yielded for our three methods in prediction of new candidate
targets for a given drug, and NBI exhibited the highest predictive
accuracy. Therefore, NBI could be a powerful tool in drug
repositioning.
Since NBI only utilized known DTI information, for a new drug
without known target information in the training set, NBI could
not predict targets for this new drug. This is a weakness of the
method. However, potential targets of a new drug can be pre-
dicted by integrating DBSI, TBSI and NBI together. We are
actively developing new network inference method by integrating
drugs, proteins and phenotype features based on diffusion theory
[32]. Our methods could also be used in prediction of other
biological networks, such as protein-protein interactions, drug-
gene, gene-disease, and drug-disease networks, by integrating
additional similarity measures among diseases, genes, and drugs
[33–35].
Polypharmacological features of new DPP-IV inhibitor
Montelukast, antagonist of cysteinyl leukotriene 1 receptor,
was marketed in the US and other countries by Merck with the
brand name SingulairH. Although Langlois et al. reported that
Figure 3. The drug–target (DT) bipartite network, in which a drug node (circle) and a target node (square) are connected to each
other by grey edge if the target is annotated to have known experimental interactions with the drug in DrugBank. The DT network
was generated using known FDA-approved small molecule DT interactions. The size of the drug node is the fraction of the number of targets that the
drug linked in DrugBank. The size of the target node is the fraction of the number of drugs that the target linked in DrugBank. Color codes are given
in the legend. Drug nodes (circles) are colored according to their Anatomical Therapeutic Chemical Classification. The graph was prepared by
Cytoscape (http://www.cytoscape.org/).
doi:10.1371/journal.pcbi.1002503.g003
Drug Repositioning via Network-Based Inference
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leukotriene-independent mechanism recently [36], there is no
report about its binding with DPP-IV so far. Herein, montelukast
was predicted and validated as a new DPP-IV inhibitor with
IC50=9.79 mM. Recently, Faul et al. found that oral administra-
tion of montelukast could change the weak level of Insulin in small
scale clinical experiment [37]. Therefore, it is reasonable to
deduce that montelukast might have new potential indication in
anti-diabetic treatment via inhibiting DPP-IV (Figure 7). Com-
paring the structural similarity between montelukast and sitaglip-
tin, a classical DPP-IV inhibitor, the Tanimoto similarity based on
MACCS keys [38] was only 0.38, which confirmed that NBI could
successfully predict novel structural skeleton molecules for a given
target.
Polypharmacological features of new ER ligands
Diclofenac is an acetic acid nonsteroidal antiinflammatory
drug (NSAID) with analgesic and antipyretic properties, and
widely used to treat pain, dysmenorrhea, ocular inflammation, and
so on. In the past decades, the anti-inflammatory effects of diclo-
fenac were thought to be linked with inhibition of both leukocyte
migration and cyclooxygenase (COX-1 and COX-2), leading to
the peripheral inhibition of prostaglandin synthesis [23]. Herein,
we reported that diclofenac targeted ERa and ERb with IC50
values of 7.59 and 2.32 mM, respectively for the first time
(Figure 4). There were a few similar examples to show NSAIDs
targeting nuclear receptors recently. Zhou et al. reported that
sulindac could induce apoptosis by binding to retinoid X receptor
a (RXRa) [39], while Lehmann et al. found that indomethacin
could activate the peroxisome proliferator-activated receptors a
and b [40]. There were also several reports to show that oral
administration of ER ligands had neuroprotective and anti-
inflammatory effects [41]. Since ERa and ERb are widely
expressed in several tissues including central nervous system,
cardiovascular system, gastrointestinal system, and immune system
[42], therefore the anti-inflammatory and neuroprotective effects
of diclofenac might be resulted from the novel biological pathways
of inhibition to ERa and ERb (Figure 7).
Simvastatin, the methylated form of lovastatin, is an
antilipemic agent which inhibits HMG-CoA reductase [23].
Here we identified that simvastatin could inhibit ERb with
IC50=3.12 mM. There is some evidence to support our finding.
For example, Wolozin et al. reported that simvastatin was
associated with a strong reduction in the incidence of dementia,
Alzheimer’s disease (AD) and Parkinson’s disease (PD) [43,44];
several studies proved that estrogen treatment was effective in
many neurodegenerative disease models [41,45]; and statins were
also found to have inhibitory effects on the proliferation of human
breast cancer cells [46]. Therefore, the strong reduction in the
incidence of dementia and PD and the inhibitory effects of the
Figure 4. Predicted and bioassay results of new identified drug-target indications for five known approved drugs. Data shown are the
mean for at least triplicate measurements.
aOriginal pharmacological target information was extracted from DrugBank (http://www.DrugBank.ca/).
b50% relatively effective concentration is the concentration of the tested chemical showing 50% of agonistic activity of the maximum activity of E2.
REC50 provides the estrogenic activity relative to that of E2.
cAntiproliferative activities were assayed on human MDA-MB-231 breast cancer cell line
by MTT assays. IC50: half maximal inhibitory concentration, EC50: half maximal effective concentration, ER: Estrogen Receptors, DPP-IV: dipeptidyl
peptidase-IV.
doi:10.1371/journal.pcbi.1002503.g004
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the potential novel biological pathway of inhibition to ERb by
simvastatin in Figure 7.
Ketoconazole and Itraconazole, as 14-a demethylase
(CYP51A1) inhibitors, are synthetic antifungal drugs [23] and
could be used to treat refractory bone pain and neurologic injury
in patients with advanced metastatic prostate cancer [26,27]. In
this study, both drugs were identified to bind to ERa and ERb
with IC50 or EC50 value less than 1 mM (Figure 5). 14-a
demethylase and ER did not share any common features in
structures or functions, but they were deduced to have the same
ligands by NBI method. The data showed that the therapeutic
Figure 5. Dose-response curves of experimentally validated polypharmacology activities on estrogen receptor (ER) and dipeptidyl
peptidase-IV (DPP-IV). Dose-response curves for inhibitive activation: montelukast to DPP-IV (A), for transcriptional activation: tamoxifen (Tam) to
ERa (black solid line) and ERb (red dash line) (B), diclofenac to ERa (black solid line) and ERb (red dash line) (C), simvastatin to ERb (D), ketoconazole to
ERb (E), itraconazole to ERa (F), itraconazole to ERb (G). In A–G, error bars were presented as the mean +SD (standard deviation) of three duplicate
determinations.
doi:10.1371/journal.pcbi.1002503.g005
Drug Repositioning via Network-Based Inference
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selective inhibition of ERb by ketoconazole.
In last decades, tissue- or subtype-selective ER modulators
(SERM) showed great advantages in clinic due to less adverse side
effects [47,48]. As shown in Figure 4, ketoconazole selectively
inhibit ERb with IC50=0.79 mM, and it did not show any
antagonistic or agonistic activity to ERa. However, itraconazole
was a dual-profile compound, which showed agonistic activity on
ERa but a higher antagonistic activity on ERb than the classical
anti-breast cancer drug tamoxifen (Figure 5). Both ketoconazole
and itraconazole could serve as leads for the discovery of novel
oral SERM.
Materials and Methods
Data preparation
Benchmark data sets. All DTI data in the benchmark data
sets were collected from KEGG BRITE [49], BRENDA [50],
SuperTarget [51] and DrugBank [23]. As listed in Table S1, the
numbers of known drugs in each data set were 445, 210, 223 and
54; while the numbers of targets in the data sets were 664, 204, 95
and 26 for enzymes, ion channels, GPCRs and nuclear receptors,
respectively. The corresponding numbers of known interactions
were 2926, 1476, 635 and 90. Further description about the data
sets can be found in the original paper [17].
DrugBank database. The DrugBank database (accessed on
August 25, 2010) was downloaded from the website: http://www.
drugbank.ca/ [23]. The initial database contained 6,796 drug
entries including 1,437 FDA-approved drugs and 5,174 experi-
mental drugs. Entries containing inorganic compounds, non-
covalent complexes, biotechnology drugs and mixtures were
excluded. The refined database contained 12,483 DTIs, among
which 2,988 ones were based on FDA-approved drugs.
All data sets used in this study are available online: http://www.
lmmd.org/database/dti/.
Method description
Denoting the drug set as D~fd1,d2,...,dng and target set as
T~ft1,t2,...,tmg, the DTI can be described as a bipartite DT
graph G(D,T,E), where E~feij : di[D,tj[Tg. A link is drawn
between di and tj when the drug di is associated with the target tj.
The DT bipartite network can be presented by an n|m adjacent
matrix faijg, where aij~1 if di and tj is linked, otherwise aij~0.
Drug-based similarity inference (DBSI). The basic idea of
this method is: if a drug interacts with a target, then other drugs
similar to the drug will be recommended to the target (Figure 1A).
For a DT pair di{tj, a linkage between di and tj is determined by
the following predicted score:
vD
ij ~
P n
l~1,l=i
SC(di,dl)alj
P n
l~1,l=i
SC(di,dl)
, ð1Þ
where SC(di,dl) is 2D chemical similarity between drugs di and dl,
which was calculated by SIMCOMP [52] here.
Target-based similarity inference (TBSI). The main idea
of this method is: if a drug interacts with a target, then the drug
will be recommended to other targets with similar sequences to the
target (Figure 1B). For a DT pair di{tj, a linkage between di and
tj is determined by the following predicted score:
vT
ij ~
P m
l~1,l=j
Sg(tj,tl)ail
P m
l~1,l=j
Sg(tj,tl)
ð2Þ
Where Sg(tj,tl) indicates the genomic sequence similarity between
targets tj and tl, which was calculated by a normalized version of
Smith-Waterman scores [17] here. All primary sequences of the
targets were obtained from the KEGG GENES database.
Network-based inference (NBI). Denoting f0(o)~aoj,
o[f1,2,   ,ng as the initial resource of drug do, for a target tj,
and f(i) as the final resource of drug di. As shown in Figure 1C,
for a general DT bipartite network, the final resource (score) f(i)
after two-step diffusion is:
f(i)~
X m
l~1
ail
k(tl)
X n
o~1
aolf0(o)
k(do)
ð3Þ
Figure 6. Dose-response curves of the antiproliferative poten-
cies for ketoconazole (A) and simvastatin (B) on human MDA-
MB-231 breast cancer cell lines by MTT assay. Error bars are
presented as the +SD (standard deviation) of three duplicate
determinations.
doi:10.1371/journal.pcbi.1002503.g006
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P m
s~1
aos denotes the number of the targets that
interact with do, and k(tl)~
P n
s~1
asl represents the number of the
drugs that interact with tl.
The resource allocation process can be written as the matrix
form as f
I
j~Wf
I
0j, where, f
I
0j is the column vector of f0, and
W~fwpqgn|n~ 1
k(dq)
P m
l~1
aplaql
k(tl)
  
n|n
could be considered as
the transfer matrix. f
I
j is the final configuration of resource on
drugs.
For three methods, all tj’s unconnected drugs which are sorted
in a descending order, constitute the recommendation list of the
target tj. The drugs with the high predictive score in the list are
more likely to interact with target tj.
Performance assessment
To test the performance of the methods, 10-fold cross-validation
approach was applied and each result was yielded by recalculating
30 times. For each data set, all the DTIs wererandomly divided into
10 parts with equal size. Each part was taken in turn as the test set,
while the remaining nine parts were served as the training set. With
the randomly splitting, some targets (ordrugs) may be just in the test
set and the corresponding links without any information in the
training set could not be predicted with the NBI method. Such links
were not considered in the performance assessment.
Three parameters, AUC, precision (P) and recall (R), were
calculated to assess the performance. The AUC value is obtained
by calculating ranking score, which can be denoted as rij~
qij
n{kj
,
where n{kj is the length of the recommendation list. And the
average ranking score of the links in the test set is:
r~ 1
EP jj
P
ij[EP
qij
n{kj
, where EP is the test set. And the AUC value
is just equal to 1{r. Since the links in the test set are actual DTIs,
a good algorithm is expected to give good prediction for them,
thus leading to large AUC.
P can be obtained from P~
1
m
Pm
j~1 NjL
L
,w h e r eNjL is the
number of true positive predictions in the top L drugs in the
recommendation list of target tj.A n dR is defined as R~ 1
m
P m
j~1
NjL
lj
,
where lj is the number of target tj’s missing links. Large Pand Rmean
that more links in the gold standard interactions are predicted out.
Prediction of drug-target interactions
Considering all DTI as known information, we calculated the
recommendation list with top predictive scores via NBI method for
Figure 7. Discovered drug-target, target-disease and disease-gene associations network. Grey arrows denote the old drug-target
interactions, grey edges denote the old target-disease associations and blue edges denote the known disease-gene associations, which were
extracted from DrugBank, Online Mendelian Inheritance in Man (OMIM) Morbid Map and literature reports (The further data were given in Table
S7). Red arrows among approved drug nodes (cyan circle) and target nodes (yellow squares) denote the new discovered drug-target
interactions in this study. Red dotted edges denote new target-disease associations discovered in this study. Cyan circle: drug node, red square:
on-target (Primary targets annotated in DrugBank), grey square: off-target, yellow square: new off-target (new discovered target for a given
drug validated in this study), violet square: disease node, green regular hexagon: gene. The graph was prepared by Cytoscape (http://www.
cytoscape.org/).
doi:10.1371/journal.pcbi.1002503.g007
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the topside of the list should be more likely to interact with the
given targets, and the corresponding new DTIs were predicted.
The full predicted lists of all data sets mentioned above are free
available online: http://www.lmmd.org/database/dti/.
Experimental validation
Compound purchase. Totally 40 purchasable approved drugs
(Tables S4, S5, S6) were selected from the top recommendation lists
for ERs and DPP-IV and purchased from the National Center for
Drug Screening (http://www.screen.org.cn/), Shanghai, China.
Dipeptidyl peptidase-IV inhibition assay. The inhibitory
effects of compounds on human recombinant DPP-IV was
determined using a DPP-IV Drug Discovery Kit (Biomol, USA)
according to the manufacturer’s instructions. The activity of DPP-
IV was detected in a Synergy
TM 2 Multi-Mode Microplate Reader
(BioTek) at an excitation wavelength of 380 nm and an emission
wavelength of 460 nm. P32/98 (10 mM) was used as a positive
compound. IC50 values were determined using the GraphPad
Prism 4 software with three independent determinations.
Yeast two-hybrid system-based assay. To evaluate the
agonistic or antagonistic activities of the compounds on ER, a
yeast two-hybrid system was constructed by yeast co-transforma-
tion with pGBKT7-ERa/bLBD and pGADT7-SRC1 according
to the lithium acetate method [53]. The combination plasmid
pGBKT7-ERa/bLBD (amino acid residues 301–553 of ERa and
248–510 of ERb) and pGADT7-SRC1 (amino acid residues 613–
773) was prepared as described previously [54]. Butyl 4-
(butyryloxy) benzoate functions as a new selective ERb agonist
and induces GLUT4 expression in CHO-K1 cells. After co-
transforming the two constructs into yeast strain AH109, we
successfully evaluated ER/SRC1 interactions by conducting a
convenient a-galactosidase assay. Yeast transformants were
incubated with either a control vehicle (DMSO) or the indicated
compounds for 24 h in hERa/b agonist testing, and in antagonist
assays 1 nM E2 was added. The a-galactosidase activity was then
measured using p-nitrophenyl a-D-galactopyranoside as the
substrate, according to the Clontech Yeast Protocol. The a-
galactosidase activity was calculated according to equation 4:
a   galactosidase activity ½milliunits=(mL|cell) 
~
OD410|Vf|1000
(e|b)|t|Vi|OD600 ð4Þ
where t is the elapsed time of incubation (min), Vf is the final
volume of assay (200 mL), Vi is the volume of culture medium
supernatant added (16 mL), OD600 is the optical density of
overnight culture, and e6b is the p-nitrophenol molar absorptivity
at 410 nm6the light path (cm)=10.5 mL/mmol.
MTT assays. Cell proliferation was quantified by MTT assay.
MDA-MB-231cellswereseededata density of1.5610
4 ina 96-well
plate with DMEM/F12 supplemented with 10% charcoal stripped
FBS without phenol red, and then incubated with the tested
compounds in humidified air containing 5% CO2 at 37uC. After
incubation for 24 h, 20 mL of 5 mg/mL MTT was added and
incubated for another 4 h. Then the converted dye was dissolved in
100 mL of DMSO and the absorbance was measured at 570 nm.
Supporting Information
Figure S1 The bipartite Drug–target network (DT network)
graph for four benchmark data sets: enzymes (red), ion channels
(orange), GPCRs (blue), nuclear receptors (black). Circles and
rectangles correspond to drug and target nodes, respectively. A
link is placed between a drug node and a target node if the protein
is a known target of that drug. The size of the drug node is the
fraction of the number of targets that the drug have with known
experimental evidence. The size of the target node is the fraction
of the number of drugs that the target have with known ex-
perimental evidence. The graph was prepared by Cytoscape
(http://www.cytoscape.org/).
(TIF)
Figure S2 The precision (P) versus the predicted drugs length (L)
with the three different methods by 30 simulation times of 10-fold
cross-validation test to predict new approved drugs to a given
target (protein) for four benchmark data sets: (a) enzymes, (b) ion
channels, (c) GPCRs and (d) nuclear receptors, (e) the log-log plot
of P versus L for the enzyme data. DBSI: Drug-Based Similarity
Inference (dot dash curve), TBSI: Target-Based Similarity
Inference (solid curve), NBI: Network-based Inference (dash
curve).
(TIF)
Figure S3 The recall (R) versus the predicted drugs length (L)
with the three different methods by 30 simulation times of 10-fold
cross-validation test to predict new approved drugs to a given
target (protein) for four benchmark data sets: (a) enzymes, (b) ion
channels, (c) GPCRs, (d) nuclear receptors. DBSI: Drug-Based
Similarity Inference (dot dash curve), TBSI: Target-Based
Similarity Inference (solid curve), NBI: Network-based Inference
(dash curve).
(TIF)
Figure S4 The performance of the network-based inference
(NBI) method on the DrugBank data sets by 30 simulation times of
10-fold cross-validation test. (a) the receiver operating character-
istic (ROC) curve, (b) precision (P) versus the predicted drugs length
(L), (c) recall (R) versus the predicted drugs length (L), approved:
data set of approved small molecular drugs in DrugBank, global:
data set of approved and experimentally investigated small
molecular drugs in DrugBank, FPR: false positive rate and TPR:
true positive rate.
(TIF)
Figure S5 The box-plot of recalls (with the prediction list length
L~10) in the case of predicting new approved drugs for a given
target by 30 simulation times of 10-fold cross-validation test. The
green dash are plotted to distinguish the data sets, and three
different methods are marked on the figure. DBSI: Drug-Based
Similarity Inference, TBSI: Target-Based Similarity Inference,
NBI: Network-based Inference, R: recall.
(TIF)
Figure S6 The receiver operating characteristic (ROC) curve
with the three different methods by 30 simulation times of 10-fold
cross-validation test to predict new targets to a given drug, testing
on four benchmark data sets: (a) enzymes, (b) ion channels, (c)
GPCRs and (d) nuclear receptors. DBSI: Drug-Based Similarity
Inference (dot dash curve), TBSI: Target-Based Similarity
Inference (solid curve), NBI: Network-based Inference (dash
curve).
(TIF)
Table S1 Statistic results of all known drug-target interaction
(DTI) data sets used in this study.
(PDF)
Table S2 The performance of the area under receiver operating
characteristic (AUC) for four benchmark data sets using three
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validation test.
(PDF)
Table S3 Recall on the valid recommendation list length for all
data sets using the NBI method by simulation 30 times of 10-fold
cross validation test.
(PDF)
Table S4 The inhibitory activities of 9 approved drugs on
dipeptidyl peptidase-IV.
(PDF)
Table S5 The agonistic and antagonistic activities of approved
drugs for estrogen receptor a.
(PDF)
Table S6 The agonistic and antagonistic activities of approved
drugs for estrogen receptor b.
(PDF)
Table S7 The detailed description of drug-gene-disease associ-
ations for five approved drugs (which were extracted from
DrugBank and Online Mendelian Inheritance in Man (OMIM)
Morbid Map on May, 2011).
(PDF)
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